Abstract
The $11.1bn global vaccines market demonstrated flat y-o-y growth in 2008 as
per IMS Health. The combination of new biotechnology research techniques and
manufacturing technologies have created a new vibrant vaccine business. It is
now a business that target larger markets amid increasing demand, and improved
profitability. The World Health Organization estimates that there are
currently more than 75 vaccines at various stages of development for a variety
of diseases. AIDs, diarrhea, pneumococcal disease, cervical cancer, and even
smoking are now being addressed by vaccine manufacturers.Although,
predominantly indicated for prophylactic management of infectious diseases,
lately novel therapeutic vaccines are developed for chronic infections such as
cancer and hepatitis. Little progress has been made so far, but this remains a
potential high-growth area and presents significant market opportunity.
Remarkably despite being in existence for over a century in modern medical
practice, the vaccines market is one where generic penetration has been the
least. Such low penetration rate is attributable to high entry barriers due to
lack of deep manufacturing expertise and large economies of scale.Since the
development of vaccines targeted at adults and especially the elderly, age
based product development has been one of the key strategies of vaccine
makers. Hence, the report discusses the vaccines market as pediatric and adult
segments and details each based on major indications. The pediatric segment
discusses indications such as pneumococcal, diphtheria/tetanus/pertussis
(DTP), measles/mumps/rubella (MMR), rotaviral, meningococcal and miscellaneous
infections. The adult segment discusses indications such as hepatitis,
influenza, human papillomavirus and other infections.
| 
View Cart
